Isotechnika: FDA Oks To Begin Phase 3 Kidney Transplant Trials For Voclosporin NASDAQ The primary endpoint of the trial will be defined as non-inferiority in biopsy proven acute rejection, or BPAR, episodes with patients receiving voclosporin for six months as compared to tacrolimus. A key secondary endpoint will be the incidence of New ... |
